These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15782549)

  • 1. Modulation of gene expression by siRNA in hematopoietic cells.
    Scherr M; Eder M
    Curr Opin Drug Discov Devel; 2005 Mar; 8(2):262-9. PubMed ID: 15782549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNAi in functional genomics.
    Scherr M; Eder M
    Curr Opin Mol Ther; 2004 Apr; 6(2):129-35. PubMed ID: 15195923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA interference (RNAi) in hematology.
    Scherr M; Steinmann D; Eder M
    Ann Hematol; 2004 Jan; 83(1):1-8. PubMed ID: 14574462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncology studies using siRNA libraries: the dawn of RNAi-based genomics.
    Sachse C; Echeverri CJ
    Oncogene; 2004 Nov; 23(51):8384-91. PubMed ID: 15517020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide application of RNAi to the discovery of potential drug targets.
    Ito M; Kawano K; Miyagishi M; Taira K
    FEBS Lett; 2005 Oct; 579(26):5988-95. PubMed ID: 16153642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choice of the adequate detection time for the accurate evaluation of the efficiency of siRNA-induced gene silencing.
    Choi I; Cho BR; Kim D; Miyagawa S; Kubo T; Kim JY; Park CG; Hwang WS; Lee JS; Ahn C
    J Biotechnol; 2005 Nov; 120(3):251-61. PubMed ID: 16095743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tightly regulated and reversibly inducible siRNA expression system for conditional RNAi-mediated gene silencing in mammalian cells.
    Wu RH; Cheng TL; Lo SR; Hsu HC; Hung CF; Teng CF; Wu MP; Tsai WH; Chang WT
    J Gene Med; 2007 Jul; 9(7):620-34. PubMed ID: 17486668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing.
    Luo Q; Kang Q; Song WX; Luu HH; Luo X; An N; Luo J; Deng ZL; Jiang W; Yin H; Chen J; Sharff KA; Tang N; Bennett E; Haydon RC; He TC
    Gene; 2007 Jun; 395(1-2):160-9. PubMed ID: 17449199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Application of RNAi library to oncology investigation].
    Weng DH; Wang SX; Ma D
    Ai Zheng; 2008 Nov; 27(11):1229-32. PubMed ID: 19000460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1-specific RNA interference.
    Boden D; Pusch O; Ramratnam B
    Curr Opin Mol Ther; 2004 Aug; 6(4):373-80. PubMed ID: 15468596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA interference in mice.
    Kühn R; Streif S; Wurst W
    Handb Exp Pharmacol; 2007; (178):149-76. PubMed ID: 17203655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.
    Sun Y; Li Z; Li L; Li J; Liu X; Li W
    Int J Mol Med; 2007 Apr; 19(4):705-11. PubMed ID: 17334648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference as a novel and powerful tool in immunopharmacological research.
    Kong Y; Ruan L; Ma L; Cui Y; Wang JM; Le Y
    Int Immunopharmacol; 2007 Apr; 7(4):417-26. PubMed ID: 17321464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA interference for the identification of disease-associated genes.
    Nencioni A; Sandy P; Dillon C; Kissler S; Blume-Jensen P; Van Parijs L
    Curr Opin Mol Ther; 2004 Apr; 6(2):136-40. PubMed ID: 15195924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vector-based RNAi approaches for stable, inducible and genome-wide screens.
    Fewell GD; Schmitt K
    Drug Discov Today; 2006 Nov; 11(21-22):975-82. PubMed ID: 17055406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient and targeted delivery of siRNA in vivo.
    Shim MS; Kwon YJ
    FEBS J; 2010 Dec; 277(23):4814-27. PubMed ID: 21078116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
    Takahashi Y; Nishikawa M; Takakura Y
    Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A
    J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using RNAi in the clinic.
    Dev KK
    IDrugs; 2006 Apr; 9(4):279-82. PubMed ID: 16596482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.